AB0248 LIPID PROFILE CHANGES FROM PRE-CLINICAL TO ESTABLISHED RHEUMATOID ARTHRITIS: A 12 YEARS FOLLOWUP PILOT STUDY

Background Patients with rheumatoid arthritis (RA) have an increased risk for developing cardiovascular diseases (CVD). This is partly due to the systemic inflammation characteristic disease, but also prevalence of ‘traditional’ factors such as dyslipidemia. The in RA often leads catabolism lipids, resulting a subsequent decrease HDL and LDL, while treatment anti-inflammatory medication reverses these effects. decreased cholesterol level active disease is, unexpectedly, associated incidence CVD (the lipid paradox). Additionally, we previously demonstrated pro-atherogenic profile changes preclinical patients. Objectives To explore patients through different phases i.e. from stage onset biological modifying anti-rheumatic drugs (bDMARDs). Methods Thirty-nine consecutive who were included both Reade’s prevention cohort current study. consisted individuals arthralgia factor and/or anti-citrullinated protein antibodies without arthritis, comprised using bDMARDs. Lipid spectrum was measured longitudinally, at following points course identified each patient (time baseline natural progression): 1.Baseline, months prior diagnosis (Start Prevention cohort) 2.Moment (End 3.Period between start bDMARD 4.Start bDMARDs 5-7.Continued Results From baseline, high density lipoprotein (HDLc) apolipoprotein A1 (ApoA1) up treatment, thereafter they slightly decreased. Low (LDLc) B (ApoB) higher activity, increasing again after starting therapy. Total cholesterol/HDL ratio substantially onwards stabilized phase. Lipoprotein(a) (Lp(a)) bDMARDs, which it stabilized. Figure 1 shows progression HDLc, LDLc total (TC) plotted against C-reactive (CRP) over time. 1. Time parameters vs activity. CRP = protein, Dx diagnosis, TC cholesterol, high-density lipoprotein, LDL low-density Conclusion Our study uniquely change during disease. While LDLc, ApoB HDLc ApoA1 increased, affirming expectations. Larger studies are necessary accurately elucidate development lipids stages patients, better understand one key RA. References [1]van Halm, V. P. et al. (2007). Lipids inflammation: serial measurements blood donors later developed arthritis. Annals rheumatic , 66 (2), 184–188. Disclosure Interests None declared